Cargando…
Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radio...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/ https://www.ncbi.nlm.nih.gov/pubmed/28968954 http://dx.doi.org/10.18632/oncotarget.16399 |
_version_ | 1783265681023696896 |
---|---|
author | Lin, Huan Chen, Ze-Tan Zhu, Xiao-Dong Li, Ling Qu, Song Wei, Zhao Su, Fang Wei, Jing-Ni Liang, Zhong-Guo Mo, Qi-Yan Wu, Jiang-Bo Meng, Hui-Ling |
author_facet | Lin, Huan Chen, Ze-Tan Zhu, Xiao-Dong Li, Ling Qu, Song Wei, Zhao Su, Fang Wei, Jing-Ni Liang, Zhong-Guo Mo, Qi-Yan Wu, Jiang-Bo Meng, Hui-Ling |
author_sort | Lin, Huan |
collection | PubMed |
description | The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radioresistant NPC was significantly higher than that with radiosensitive NPC. In vitro, the CD166 positive rate in the CNE2 cell membrane was significantly lower than that in the CNE2R cell membrane. The magnetic-activated cell sorting technology was used to obtain CNE-2R-CD166(+) and CNE-2R-CD166(−) cell lines. Then radiosensitivity, cell proliferation, and apoptosis were assessed using colony formation assay, cell counting kit 8 assay (CCK-8), and flow cytometry, respectively. The radiation sensitivity ratio was 1.28, indicating that the CNE2R-CD166(−) cells had a stronger radiation sensitivity. The result of CCK-8 assay indicated that the survival fraction of CNE2R-CD166(+) cells was significantly higher than that of CNE2R-CD166(−) cells. The apoptotic rate of CNE2R-CD166(+) cells was significantly lower than that of CNE2R-CD166(−) cells. Our data demonstrate that the secreted protein CD166 may be can used as a biomarker for predicting the response of NPC to radiotherapy. |
format | Online Article Text |
id | pubmed-5609886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56098862017-09-29 Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy Lin, Huan Chen, Ze-Tan Zhu, Xiao-Dong Li, Ling Qu, Song Wei, Zhao Su, Fang Wei, Jing-Ni Liang, Zhong-Guo Mo, Qi-Yan Wu, Jiang-Bo Meng, Hui-Ling Oncotarget Research Paper The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radioresistant NPC was significantly higher than that with radiosensitive NPC. In vitro, the CD166 positive rate in the CNE2 cell membrane was significantly lower than that in the CNE2R cell membrane. The magnetic-activated cell sorting technology was used to obtain CNE-2R-CD166(+) and CNE-2R-CD166(−) cell lines. Then radiosensitivity, cell proliferation, and apoptosis were assessed using colony formation assay, cell counting kit 8 assay (CCK-8), and flow cytometry, respectively. The radiation sensitivity ratio was 1.28, indicating that the CNE2R-CD166(−) cells had a stronger radiation sensitivity. The result of CCK-8 assay indicated that the survival fraction of CNE2R-CD166(+) cells was significantly higher than that of CNE2R-CD166(−) cells. The apoptotic rate of CNE2R-CD166(+) cells was significantly lower than that of CNE2R-CD166(−) cells. Our data demonstrate that the secreted protein CD166 may be can used as a biomarker for predicting the response of NPC to radiotherapy. Impact Journals LLC 2017-03-21 /pmc/articles/PMC5609886/ /pubmed/28968954 http://dx.doi.org/10.18632/oncotarget.16399 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Lin, Huan Chen, Ze-Tan Zhu, Xiao-Dong Li, Ling Qu, Song Wei, Zhao Su, Fang Wei, Jing-Ni Liang, Zhong-Guo Mo, Qi-Yan Wu, Jiang-Bo Meng, Hui-Ling Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title | Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title_full | Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title_fullStr | Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title_full_unstemmed | Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title_short | Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
title_sort | serum cd166: a novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/ https://www.ncbi.nlm.nih.gov/pubmed/28968954 http://dx.doi.org/10.18632/oncotarget.16399 |
work_keys_str_mv | AT linhuan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT chenzetan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT zhuxiaodong serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT liling serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT qusong serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT weizhao serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT sufang serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT weijingni serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT liangzhongguo serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT moqiyan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT wujiangbo serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy AT menghuiling serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy |